Navigation Links
Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
Date:12/7/2009

Acquisition broadens Merrimack’s capabilities to discover and develop systems biology-driven therapeutics to include small molecules, chemotherapy and RNAi candidates and technologies for cancer

Cambridge, MA (PRWEB) December 7, 2009 -- Merrimack Pharmaceuticals, Inc., announced today that it has acquired Hermes Biosciences, Inc. a private biotechnology company based in South San Francisco, California. Hermes specializes in targeted drug delivery technologies for therapeutic and other biomedical applications using lipidic nano-carriers and antibodies as targeting agents.    

“The acquisition of Hermes, is part of Merrimack’s strategy to apply our systems biology approach to drug discovery and development to an expanding array of disease-fighting targets and technologies,” siad Robert Mulroy, President and CEO of Merrimack.

“We believe that coupling Merrimack’s approach of identifying critical targets through systems analysis with our innovative drug delivery technologies creates great potential to generate truly novel therapies that can provide significant benefit to cancer patients,” said Dr. John Park, President, CEO and a founder of Hermes.
Merrimack’s proprietary Network Biology platform applies techniques from the fields of computational modeling, high throughput biology and engineering to understand cell system dynamics and develop therapeutics to address cell malfunctions in a disease state. The first candidates to be developed out of this approach are MM-121, a first-in-class ErbB3 antagonist, and MM-111, a bispecific antibody targeting ErbB2 and ErbB3. Both candidates are in Phase 1 development and are expected to enter Phase 2 in 2010.

Hermes was founded in 1998 by a group of leading cancer physicians and scientists at the University of California, San Francisco, to develop lipidic nano-carriers to allow for targeted delivery of small molecule drugs, including chemotherapies, with the goal of improving cancer treatment safety and efficacy. Hermes’ lead candidate, MM-398, is a nanoliposomal formulation of CPT-11 that is currently in Phase 2 trials with a partner for multiple cancer indications (under the designation of PEP02). Merrimack expects to initiate clinical development with the next Hermes product candidate, MM-302, an antibody-targeted lipidic nano-carrier for cancer therapy, in 2010. Merrimack is privately-held and based in Cambridge, Massachusetts.

About Merrimack
Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for cancer and autoimmune disease. Its first two oncology pipeline candidates, MM-121 and MM-111, are currently in clinical development. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high-throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and well-tolerated therapeutics. Merrimack is a privately-held company based in Cambridge, Massachusetts.

Contacts
Kathleen Petrozzelli, Corporate Communications, 617-441-1043, kpetrozzelli(at)merrimackpharma(dot)com,
Betsy Raymond Stevenson, RaymondStevenson Healthcare Comms, 860-984-1424, betsy(at)raymondstevenson(dot)com

###

Read the full story at http://www.prweb.com/releases/2009/12MerrimackHermes/prweb3302594.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
2. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
4. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
5. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in ... 8:30aET on RFD-TV. , With global population estimates nearing ten billion people by ... feed a growing nation. At the same time, many of our valuable resources are ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... consulting for microscopy and surface analysis, Nanoscience Instruments is now expanding into ... a broad range of contract analysis services for advanced applications. Services will ...
Breaking Biology Technology:
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):